Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 13 years, Kissei Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 214.60% per year. The lowest was -68.10% per year. And the median was 7.95% per year.
Kissei Pharmaceutical Co (OTCPK:KSPHF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Kissei Pharmaceutical Co Earnings per Share (Diluted) Related Terms
Kissei Pharmaceutical Co Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Kissei Pharmaceutical Co's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kissei Pharmaceutical Co Earnings per Share (Diluted) Chart
KSPHF vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kissei Pharmaceutical Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kissei Pharmaceutical Co PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kissei Pharmaceutical Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Kissei Pharmaceutical Co's PE Ratio falls into.
Kissei Pharmaceutical Co Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Kissei Pharmaceutical Co's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $2.16 mean?
Kissei Pharmaceutical Co (KSPHF) has a Earnings per Share (Diluted) of $2.16 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Kissei Pharmaceutical Co and its competitors. According to the industry distribution chart, Kissei Pharmaceutical Co ranks #999999 out of 785 companies in the Drug Manufacturers industry.
Is Kissei Pharmaceutical Co's Earnings per Share (Diluted) too high?
Kissei Pharmaceutical Co's current Earnings per Share (Diluted) is $2.16. The Drug Manufacturers industry median Earnings per Share (Diluted) is 9.90. Kissei Pharmaceutical Co's value of $2.16 is 78.2% below this industry median. Based on the distribution chart, Kissei Pharmaceutical Co ranks #999999 out of 785 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kissei Pharmaceutical Co has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Kissei Pharmaceutical Co's Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kissei Pharmaceutical Co ranks #999999 out of 785 companies for Earnings per Share (Diluted). This places Kissei Pharmaceutical Co in the lower half of its industry. The industry median Earnings per Share (Diluted) is 9.90. Kissei Pharmaceutical Co's value of $2.16 is 78.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.90, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kissei Pharmaceutical Co's current Earnings per Share (Diluted) of $2.16 is 78.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Kissei Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kissei Pharmaceutical Co's current Earnings per Share (Diluted) is $2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kissei Pharmaceutical Co stock overvalued right now?
Kissei Pharmaceutical Co (KSPHF) has a current Earnings per Share (Diluted) of $2.16. The stock's GF Value™ is $29.35, compared to a current price of $25.77 — trading 12.2% below its estimated fair value. The current Earnings per Share (Diluted) is $2.16 and 78.2% below the Drug Manufacturers industry median of 9.90. Kissei Pharmaceutical Co's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Kissei Pharmaceutical Co (KSPHF), the current Earnings per Share (Diluted) is $2.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kissei Pharmaceutical Co (KSPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Kissei Pharmaceutical Co stock appears to be undervalued.
The current stock price of $25.77 is trading 12.2% below its estimated GF Value™ of $29.35.
Key valuation signals for KSPHF:
Earnings per Share (Diluted): $2.16
GF Value™: $29.35 vs. price of $25.77 (12.2% below fair value)
Industry Position: 78.2% below the Drug Manufacturers median (#999999 of 785)
No single metric tells the full story. See the KSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company's operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
75GF Score
Get the complete analysis for KSPHF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KSPHF has been successfully added to your 
